RHYTHM PHARMACEUTICALS, INC. Pay versus Performance
The Pay versus Performance table from each proxy statement (Item 402(v)), as tagged in its XBRL, newest proxy first. Each proxy's own figures are kept, so a year restated in a later proxy appears once per proxy. PEO is the principal executive officer; NEO means the other named executive officers (average). Total shareholder return is the value of a $100 investment.
- 2025-12-31: PEO David P. Meeker; PEO total compensation $17.54M; PEO compensation actually paid $54.16M; Other NEO average total compensation $5.59M.
- 2024-12-31: PEO David P. Meeker; PEO total compensation $14.66M; PEO compensation actually paid $18.68M; Other NEO average total compensation $4.60M.
- 2023-12-31: PEO David P. Meeker; PEO total compensation $7.23M; PEO compensation actually paid $19.01M; Other NEO average total compensation $1.97M.
- 2022-12-31: PEO David P. Meeker; PEO total compensation $3.33M; PEO compensation actually paid $24.14M; Other NEO average total compensation $1.11M.
| Fiscal year end | PEO | PEO total compensation | PEO compensation actually paid | Other NEO average total compensation | Other NEO average compensation actually paid | Total shareholder return | Peer group total shareholder return | Net income | Company-selected measure | Proxy filed |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | David P. Meeker | $17.54M | $54.16M | $5.59M | $14.70M | $360.00 | $93.71 | -$196.54K | Revenue $189.76K | 2026-04-29 |
| 2024-12-31 | David P. Meeker | $14.66M | $18.68M | $4.60M | $6.66M | $188.27 | $93.49 | -$260.60K | $130.13K | 2026-04-29 |
| 2023-12-31 | David P. Meeker | $7.23M | $19.01M | $1.97M | $4.81M | $154.61 | $94.03 | -$184.68K | $77.43K | 2026-04-29 |
| 2022-12-31 | David P. Meeker | $3.33M | $24.14M | $1.11M | $4.81M | $97.94 | $89.90 | -$181.12K | $23.64K | 2026-04-29 |
| 2021-12-31 | David P. Meeker | $6.46M | -$10.02M | $2.07M | -$775.04K | $33.57 | $100.02 | -$69.61K | $3.15K | 2026-04-29 |
| 2024-12-31 | David P. Meeker | $14.66M | $18.68M | $4.60M | $6.66M | $188.27 | $93.49 | -$260.60K | Total Revenues $130.13K | 2025-04-29 |
| 2023-12-31 | $7.23M | $19.01M | $1.97M | $4.81M | $154.61 | $94.03 | -$184.68K | $77.43K | 2025-04-29 | |
| 2022-12-31 | $3.33M | $24.14M | $1.11M | $4.81M | $97.94 | $89.90 | -$181.12K | $23.64K | 2025-04-29 | |
| 2021-12-31 | $6.46M | -$10.02M | $2.07M | -$775.04K | $33.57 | $100.02 | -$69.61K | $3.15K | 2025-04-29 | |
| 2023-12-31 | David P. Meeker | $7.23M | $19.01M | $1.97M | $4.81M | $154.61 | -$184.68K | 2024-04-26 | ||
| 2022-12-31 | $3.33M | $24.14M | $1.11M | $4.81M | $-97.94 | -$181.12K | 2024-04-26 | |||
| 2021-12-31 | $6.46M | -$10.02M | $2.07M | -$775.04K | $-33.57 | -$69.61K | 2024-04-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |